Compound 8i is a multi-target receptor tyrosine kinase inhibitor [1
]. The chemical structure matches that ascribed to the Exelixis compound XL999 presented by MedKoo, but there is no peer reviewed confirmation of this nomenclature linkage.
Compound 8i does not alter c-MET activity, so its effects can be compared to those of foretinib
which are c-MET inhibitors, to help assess the contribition that inhibition of the different kinases makes to measured outcomes (e.g.